Detectnet, developed by privately-held RadioMedix Inc. and its commercial partner Curium Pharma, was approved on September 3, 2020.Detectnet (copper Cu 64 dotatate) is a radioactive diagnostic agent indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult patients.Detectnet binds to somatostatin receptors with the highest affinity for subtype 2 receptors (SSTR2). Depending on the intensity of PET images obtained using Detectnet shows the presence and density of somatostatin receptors in tissues.Detectnet is the first FDA-approved Cu 64 diagnostic agent.